Clinical Trials Logo

Recurrent Bladder Cancer clinical trials

View clinical trials related to Recurrent Bladder Cancer.

Filter by:

NCT ID: NCT00006124 Completed - Clinical trials for Recurrent Bladder Cancer

Celecoxib in Treating Patients With Bladder Cancer

Start date: June 2000
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of bladder cancer

NCT ID: NCT00005831 Completed - Clinical trials for Stage IV Bladder Cancer

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Start date: March 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining trastuzumab with combination chemotherapy in treating patients who have locally recurrent or metastatic urinary tract cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor cells

NCT ID: NCT00004856 Terminated - Clinical trials for Stage IV Bladder Cancer

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Start date: July 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of trastuzumab in treating patients who have previously treated, locally advanced, or metastatic cancer of the urothelium. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy

NCT ID: NCT00003167 Completed - Clinical trials for Stage IV Bladder Cancer

Gene Therapy in Treating Patients With Advanced Bladder Cancer

Start date: May 1998
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer